ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
29 announcements
Parmax Pharma Ltd filed its quarterly shareholding pattern under Regulation 31. The disclosure reflects changes in promoter status following a previously concluded open offer.
Parmax Pharma Ltd will hold its 32nd Annual General Meeting on September 29, 2026. The meeting will address the adoption of financial statements and director appointments.
Parmax Pharma's promoters acquired shares via preferential allotment. This filing discloses the acquisition of equity stakes by eleven promoter-related entities.
Promoter group members Dhiren Shah and Sunil Shah acquired 22,80,444 equity shares in Parmax Pharma Ltd. The acquisition occurred via a preferential allotment on August 29, 2026.
Parmax Pharma allotted 31.37 lakh equity shares at Rs. 36.50 each and 21.45 lakh convertible warrants to various non-promoter allottees on a preferential basis.
Parmax Pharma announced the reclassification of its promoters following an open offer and share purchase agreement. Existing promoters will be reclassified under the public category.
Fedex Securities issued a post-offer advertisement for the open offer of Parmax Pharma Limited. The offer involved acquiring 26% stake at ₹42.80 per share.
Parmax Pharma received BSE's 'In-Principle' approval for a preferential issuance of 31,37,586 equity shares and 21,45,145 warrants at Rs. 36.50 per unit.
Promoters Alkesh Mahasukhlal Gopani and others sold their entire 30.81% stake in Parmax Pharma Ltd. The off-market sale of 11,52,450 shares concluded on August 13, 2026.
Sunil Chinubhai Shah and others acquired 11,52,450 shares (30.81%) of Parmax Pharma Limited. This off-market purchase via a Share Purchase Agreement increases their collective holding to 58.01%.
Parmax Pharma Limited announced the appointment of Dhiren Shah and Sunil Shah as Directors. Additionally, Ms. Salma Thobhani resigned as a Non-Executive Non-Independent Director.
Parmax Pharma Ltd reported revenue from operations of ₹8.2 Cr (+331.6% YoY) and net profit of ₹2.2 Cr for Q1 FY27.
Sunil Chinubhai Shah and others acquired 11,52,450 equity shares (30.81%) of Parmax Pharma Limited. This SPA-based acquisition increases the promoter group stake to 58.01%.
Parmax Pharma Ltd has scheduled a board meeting for August 14, 2026. The meeting's agenda includes the approval of unaudited financial results for the June quarter.
Fedex Securities submitted a Letter of Offer for Parmax Pharma Ltd. Acquirers intend to buy 23,46,250 equity shares (26% stake) from public shareholders.
Parmax Pharma Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, as required by regulatory norms.
Parmax Pharma Ltd increased authorized capital by Rs. 4 Crore to Rs. 10 Crore. New Articles of Association were adopted to align with the Companies Act, 2013.
Parmax Pharma Ltd held its 2nd EGM on July 2, 2026, to approve capital restructuring. Key resolutions included increasing authorized share capital and issuing preferential equity and warrants.
Parmax Pharma convened an EGM for July 02, 2026, to approve a ₹19.28 Crore preferential issue. The move supports working capital and general corporate purposes.
Parmax Pharma announced a Share Purchase Agreement for a change in control. The deal includes a ₹19.28 Crore preferential issuance of shares and warrants.
Acquirers launched a ₹10.04 Crore open offer for a 26% stake in Parmax Pharma Limited. This mandatory bid follows significant equity acquisitions through share purchase and preferential allotments.
Parmax Pharma's board approved a ₹19.28 Crore preferential issue of equity shares and warrants. The capital raise targets non-promoter investors to strengthen the company's financial position.
Parmax Pharma Ltd reported revenue from operations of ₹3.3 Cr (-31.2% YoY) and a net loss of ₹0.6 Cr for Q4 FY26.
Parmax Pharma Limited filed the scrutinizer's report for its Extra Ordinary General Meeting held on May 27, 2025. Shareholders approved key director appointments and re-appointments via remote e-voting.
Parmax Pharma Ltd scheduled a board meeting on May 30, 2026, to approve audited financial results for fiscal 2026. The trading window remains closed for insiders.
Parmax Pharma Limited has scheduled an Extra Ordinary General Meeting on May 27, 2026. Key agenda items include the appointment of three non-executive directors and the re-appointment of Mr. Umang Gosalia as Managing Director for five years. Remote e-voting is available from May 24 to May 26, 2026.
Parmax Pharma Ltd has approved the re-appointment of Dr. Umang Gosalia (DIN: 05153830) as Managing Director for a five-year term starting June 28, 2026. Dr. Gosalia, associated with the firm since 2016, oversees production activities. The appointment is subject to shareholder approval at the upcoming general meeting.
Parmax Pharma Ltd submitted its initial disclosure regarding the Large Corporate framework for the financial year. The company reported outstanding borrowings of ₹7.92 Crore and confirmed it does not meet the criteria to be classified as a Large Corporate under SEBI norms.
Parmax Pharma Ltd reported a net loss of ₹0.7 Cr for Q3 FY26.